Document is current
Any future updates will be listed below
-
Authors
Nadig, Ajay https://orcid.org/0000-0001-9634-2141
Replogle, Joseph M. https://orcid.org/0000-0003-1832-919X
Pogson, Angela N.
Murthy, Mukundh https://orcid.org/0009-0001-7559-2990
McCarroll, Steven A.
Weissman, Jonathan S. https://orcid.org/0000-0003-2445-670X
Robinson, Elise B. https://orcid.org/0000-0003-2314-2792
O’Connor, Luke J. https://orcid.org/0000-0003-2730-9668
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (T32GM007753, T32GM007618)
U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke (F31NS115380)
- License Information
-
More Information
Article History
Received: 24 June 2024
Accepted: 17 March 2025
First Online: 21 April 2025
Competing interests
: J.S.W. declares outside interest in 5 AM Venture, Amgen, Chroma Medicine, KSQ Therapeutics, Maze Therapeutics, Tenaya Therapeutics, Tessera Therapeutics, Ziada Therapeutics and Third Rock Ventures. J.M.R. consults for Third Rock Ventures and Maze Therapeutics, and is a consultant for and equity holder in Waypoint Bio. The remaining authors declare no competing interests.
